Organigram (OGI) to Release Quarterly Earnings on Tuesday

Organigram (TSE:OGI) is scheduled to be releasing its earnings data before the market opens on Tuesday, May 14th. Analysts expect Organigram to post earnings of C($0.08) per share for the quarter.

Organigram (TSE:OGI) last posted its quarterly earnings data on Tuesday, February 13th. The company reported C($0.19) EPS for the quarter, missing the consensus estimate of C($0.13) by C($0.06). Organigram had a negative return on equity of 54.53% and a negative net margin of 153.80%. The business had revenue of C$36.46 million for the quarter, compared to the consensus estimate of C$38.13 million.

Organigram Stock Down 2.4 %

OGI stock opened at C$2.45 on Thursday. The business has a 50 day moving average of C$2.81 and a 200 day moving average of C$2.30. The firm has a market cap of C$252.35 million, a PE ratio of -0.98, a price-to-earnings-growth ratio of 0.42 and a beta of 1.10. Organigram has a twelve month low of C$1.35 and a twelve month high of C$3.95. The company has a quick ratio of 2.62, a current ratio of 6.95 and a debt-to-equity ratio of 1.75.

Insiders Place Their Bets

In other Organigram news, Director Donald Geoffrey Machum sold 23,000 shares of the business’s stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of C$2.74, for a total transaction of C$62,964.80. 27.32% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on OGI shares. Jefferies Financial Group reduced their price objective on shares of Organigram from C$4.95 to C$4.40 and set a “buy” rating for the company in a research note on Tuesday, February 27th. Alliance Global Partners boosted their price objective on Organigram from C$2.00 to C$2.70 and gave the company a “neutral” rating in a research report on Wednesday, February 14th. Finally, ATB Capital set a C$5.25 target price on Organigram and gave the company an “outperform” rating in a research note on Wednesday, April 3rd.

About Organigram

Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.